EIB and BioVersys AG sign €20m deal to support development of antibiotics

BV100, BioVersys’ breakthrough hospital antibiotic therapy, targets one of the World Health Organization’s (WHO) top priority pathogens, resistant Acinetobacter baumannii.

EIB | Updated: 14-04-2021 15:56 IST | Created: 14-04-2021 15:56 IST
EIB and BioVersys AG sign €20m deal to support development of antibiotics
“There have been no new classes of antibiotics on the market for decades,” said EIB Vice-President Thomas Östros. Image Credit: ANI

The European Investment Bank (EIB) and BioVersys AG, a clinical-stage pharmaceutical company developing treatments for multidrug-resistant bacterial infections, today announced the signing of a €20 million venture debt transaction. The financing supports the company's research and development of a diverse pipeline of drugs that address antimicrobial resistance (AMR). AMR has resulted in the majority of our antimicrobial therapies becoming obsolete, thereby leaving the world's population susceptible to an ever-increasing range of infections. The possibility of a bacterial pandemic is already widely recognised as an imminent threat.

BV100, BioVersys' breakthrough hospital antibiotic therapy, targets one of the World Health Organization's (WHO) top priority pathogens, resistant Acinetobacter baumannii. The drug is being studied for the treatment of ventilator-associated bacterial pneumonia, which is common in COVID-19 patients. Currently, there are little to no effective and safe treatment options for this infection. Due to antibiotic resistance, infections caused by resistant Acinetobacter baumannii have a devastating mortality rate of greater than 50%. Another drug in the BioVersys pipeline is BVL-GSK098, a small molecule that is being tested for multi-drug resistant tuberculosis infections, one of the top ten killers globally, with 1.5 million deaths annually. Both BV100 and BVL-GSK098 are currently undergoing Phase 1 clinical trials.

"There have been no new classes of antibiotics on the market for decades," said EIB Vice-President Thomas Östros. "This comes at an enormous cost for people and our societies at large. If we do not manage to curb AMR, it will not only kill thousands of people every year but will also drive millions into poverty. I am therefore very pleased that the EIB can contribute to the financing of a company that might hold the key to alleviating some of the most pressing health issues we currently face."

Mariya Gabriel, European Commissioner for Innovation, Research, Culture, Education and Youth, added: "The EU stands at the forefront of addressing AMR and the challenges it presents via a number of initiatives under the EU One Health Action plan against AMR. An important pillar of the action plan is research and innovation, which can provide novel solutions and tools to prevent and treat infectious diseases. To control the spread of AMR it is essential to establish a new pipeline of antimicrobials and we are very pleased to support BioVersys in their efforts towards this goal."

"Being the first Swiss biotech company to receive a venture loan from the EIB is an independent validation of the relevance and quality of the BioVersys product pipeline. AMR has been widely recognised as the top priority health threat by the WHO, G7 and G20. BioVersys develops novel drugs addressing some of the most serious infections caused by drug-resistant bacteria. The funds from the EIB, together with our recent Series B closing of CHF 19 million, enable us to push our clinical development programmes forward and further strengthen the company as the leading European private biotech AMR player," said Marc Gitzinger, CEO and founder of BioVersys.

Since the discovery of penicillin, antibiotics have become the cornerstone of modern medicine. Antibiotic resistance poses a severe threat to the continued efficacy of these essential drugs. Traditional industry players such as large pharmaceutical companies have left the AMR space and it is now for specialised biotech companies like BioVersys to innovate and create novel products for these high unmet medical needs. Some 700 000 people already die each year due to drug-resistant diseases. According to the WHO, this figure could rise to 10 million by 2050 if no action is taken.

The urgency for novel and more robust antibiotics against resistant bacteria has been further reinforced due to COVID-19. One of the most notorious resistant bacteria, Acinetobacter baumannii, is primarily associated with hospital-acquired infections. Bacterial co-infections are a significant cause of morbidity and mortality during viral infections such as COVID-19. Reports indicate that a significant number of deceased COVID-19 patients had an untreatable secondary bacterial infection due to antimicrobial resistance.

BioVersys will receive the EIB loan in three tranches upon the completion of pre-defined milestones. The transaction is backed by the Infectious Diseases Finance Facility (IDFF) set up as part of the European Union's Horizon 2020 Programme. The IDFF is an example of successful collaboration between the European Commission and the EIB in the face of a health crisis. Through this facility, the EIB has supported European companies via total lending of more than €400 million for developing cures, vaccines and diagnostics for various infectious diseases, most prominently coronavirus.



Blockchain in Healthcare: Opportunities and challenges

The use of blockchain in healthcare is a relatively new innovation with many of its uses still being explored and related technologies being developed, improved, and scaled. ...

Debate surrounding vaccine passports and development misses bigger picture

... ...

Blockchain vs IOTA: Looking for a better alternative

... ...

For stability, Iraq needs to crack down on corruption

... ...


Latest News

Motor racing-Wolff's message to race control signals new move for F1

Formula One broke new ground on Sunday when a radio message from Mercedes boss Toto Wolff to race control during the Spanish Grand Prix was broadcast to television audiences. Wolff addressed race director Michael Masi directly when Haass Ru...

Seven dead, including suspect, in shooting at Colorado birthday party, but children spared

A man shot six people to death, including his girlfriend, before fatally shooting himself at a birthday party in Colorado Springs, Colorado, early on Sunday, sparing the children present inside a trailer at a mobile home park, officials sai...

Soccer-Premier League talking points

Talking Points from the Premier League weekendHAVE CHELSEA GAINED A PSYCHOLOGICAL EDGE Chelseas 2-1 victory over Manchester City made sure Citys title celebrations remained on hold but perhaps more importantly sent out a message to Pep Guar...

UK officials admit some markets to be subject to duties under post-Brexit deal terms - FT

Companies in freeports in Britain will not get to enjoy the full benefits of the new tax-efficient zones if they are exporting to certain countries including Canada, Norway, Switzerland and Singapore, the Financial Times reported httpson.ft...

Give Feedback